ERBB3 and metastatic neoplasm: HER3 expression is also associated with metastatic disease progression and decreased relapse-free survival in patients57, thus, HER3 is an attractive therapeutic target in NSCLC, especially due to its potential functional role in mediating resistance to targeted therapies.